ACA
TERN

Avoro Capital Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Avoro Capital Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300M Buy
5,695,000
+1,345,000
+31% +$55.2M 2.95% 13
2025
Q4 		$176M Buy
+4,350,000
New +$101M 1.73% 16

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Avoro Capital Advisors's TERN Position: Q1 2026 in Review

Avoro Capital Advisors increased its Terns Pharmaceuticals (TERN) stake by 31% in Q1 2026, buying an estimated $55.2M and bringing the position to 5,695,000 shares worth $300M. The position accounts for 2.95% of the portfolio, ranked #13.

Avoro Capital Advisors first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Avoro Capital Advisors held 5,695,000 shares of Terns Pharmaceuticals worth $300M as of Q1 2026.
  • Avoro Capital Advisors bought 1,345,000 Terns Pharmaceuticals shares in Q1 2026, an estimated $55.2M.
  • Terns Pharmaceuticals made up 2.95% of Avoro Capital Advisors's portfolio in Q1 2026, its #13 holding.
  • Avoro Capital Advisors first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.